Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New nursing model aims to ease anxiety and pain in lung cancer patients

NCT ID NCT07525908

Symptom relief Sponsor: The First Hospital of Hebei Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a 4-week nursing program based on self-efficacy theory for 300 lung cancer patients receiving CyberKnife radiation. The program included education, psychological support, and self-management training. Researchers measured changes in anxiety, pain, and quality of life compared to standard nursing care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Self-Efficacy Theory-Based Nursing Model (behavioral intervention)
What this could lead to
If successful, this nursing model could offer a simple, drug-free way to help lung cancer patients feel less anxious, have less pain, and enjoy a better quality of life during treatment.
What could go wrong
This is a completed study with 300 participants, but it only tested a behavioral program, not a new drug or cure. The results may not apply to all lung cancer patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

300 people

The number who actually took part.

Started

Oct 2023

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged between 40 and 80 years, inclusive. * Histologically or cytologically confirmed diagnosis of primary lung cancer (suitable for CyberKnife treatment). * Scheduled to receive CyberKnife stereotactic radiosurgery as a primary or palliative treatment. * Karnofsky Performance Status (KPS) score of 80-100. * Patient-Generated Subjective Global Assessment (PG-SGA) score ≤ 5. * Estimated life expectancy of at least 6 months. * Able to understand, speak, and read Mandarin Chinese. * Willing and able to provide written informed consent. Exclusion Criteria: * Presence of severe, uncontrolled cardiovascular, cerebrovascular, respiratory, hepatic, or renal diseases. * Known history of severe psychiatric disorders or cognitive impairment. * Presence of other active malignancies requiring systemic treatment. * Known severe, uncontrolled endocrine or metabolic diseases. * Significant coagulation disorders. * Previous radiotherapy to the planned CyberKnife treatment field. * Participation in another interventional clinical trial concurrently or within 30 days prior to enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety Lung neoplasms

Contacts and locations

Locations

  • First Hospital of Hebei Medical University

    Shijiazhuang, Hebei, 050000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.